Solid Tumor Profiling
Various Solid Tumors
Key Facts
About Diatech Pharmacogenetics
Diatech Pharmacogenetics is a commercial-stage diagnostics company specializing in molecular testing for precision medicine in oncology and pharmacogenetics. Leveraging over 25 years of collective experience, the company executes over 500,000 tests annually worldwide and is ISO 9001, ISO 13485, and EU IVDR certified, indicating a strong focus on quality and regulatory compliance. Its core value proposition is delivering timely, actionable genetic information to clinicians to guide therapeutic selection, aiming to improve patient outcomes by ensuring 'the right drug, for the right patient, at the right time.' The company operates as a private entity, driving adoption through its testing services, educational webinars, and a knowledge hub for the medical community.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Guardant Infinity Biomarker Discovery | Guardant Health | Development/Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| Taiho Oncology Pipeline | Otsuka Holdings | Multiple (I-III) |
| Lenvatinib + Pembrolizumab | Eisai | Phase 3 / Marketed |
| PD-1/PD-L1 Inhibitor | PeptiDream | Phase 1 |
| Cadonilimab (AK104) | Akeso | Phase III |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved / Phase 3 |
| Early I-O Pipeline | Ipsen | Pre-clinical / Phase 1 |